<SEC-DOCUMENT>0001193125-13-450003.txt : 20131121
<SEC-HEADER>0001193125-13-450003.hdr.sgml : 20131121
<ACCEPTANCE-DATETIME>20131121172155
ACCESSION NUMBER:		0001193125-13-450003
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20131121
DATE AS OF CHANGE:		20131121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-187508
		FILM NUMBER:		131236090

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d633427d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospects Supplement No. 11</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(to
Prospectus dated May&nbsp;30, 2013)</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424 (b)(4) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No. 333-187508 </B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>125,000 Shares of Series A Convertible Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>12,500,000 Shares of Common Stock Underlying the Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase up to 6,250,000 Shares of Common Stock and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>6,250,000 Shares of Common Stock Underlying the Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g633427g95w33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement supplements the prospectus dated May&nbsp;30, 2013 (the &#147;Prospectus&#148;), as supplemented by that certain
Prospectus Supplement No.&nbsp;1 dated July&nbsp;17, 2013 (&#147;Supplement No.&nbsp;1&#148;), by that certain Prospectus Supplement No.&nbsp;2 dated July&nbsp;19, 2013 (&#147;Supplement No.&nbsp;2&#148;), by that certain Prospectus Supplement
No.&nbsp;3 dated July&nbsp;24, 2013 (&#147;Supplement No.&nbsp;3&#148;), by that certain Prospectus Supplement No.&nbsp;4 dated July&nbsp;30, 2013 (&#147;Supplement No.&nbsp;4&#148;), by that certain Prospectus Supplement No.&nbsp;5 dated
August&nbsp;6, 2013 (&#147;Supplement No.&nbsp;5&#148;), by that certain Prospectus Supplement No.&nbsp;6 dated September&nbsp;4, 2013 (&#147;Supplement No.&nbsp;6&#148;), by that certain Prospectus Supplement No.&nbsp;7 dated September&nbsp;23,
2013 (&#147;Supplement No.&nbsp;7&#148;), by that certain Prospectus Supplement No.&nbsp;8 dated October&nbsp;29, 2013 (&#147;Supplement No.&nbsp;8&#148;), by that certain Prospectus Supplement No.&nbsp;9 dated November&nbsp;6, 2013
(&#147;Supplement No.&nbsp;9&#148;), and by that certain Prospectus Supplement No.&nbsp;10 dated November&nbsp;13, 2013 (&#147;Supplement No.&nbsp;10&#148;, and together with Supplement No.&nbsp;1, Supplement No.&nbsp;2, Supplement No.&nbsp;3,
Supplement No.&nbsp;4, Supplement No.&nbsp;5, Supplement No.&nbsp;6, Supplement No.&nbsp;7, Supplement No.&nbsp;8, and Supplement No.&nbsp;9, the &#147;Supplements&#148;), which form a part of our Registration Statement on Form S-1 (Registration
No.&nbsp;333-187508). This prospectus supplement is being filed to update and supplement the information in the Prospectus and the Supplements with the information contained in our current report on Form 8-K, filed with the Securities and Exchange
Commission (the &#147;Commission&#148;) on November&nbsp;21, 2013 (the &#147;Current Report&#148;). Accordingly, we have attached the Current Report to this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus, the Supplements and this prospectus supplement relate to the offer and sale of up to 125,000 shares of Series A Convertible
Preferred Stock (&#147;Preferred Stock&#148;) which are convertible into 12,500,000 shares of Common Stock, warrants to purchase up to 6,250,000 shares of our Common Stock and 6,250,000 shares of Common Stock underlying the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement should be read in conjunction with the Prospectus and the Supplements. This prospectus supplement updates and
supplements the information in the Prospectus and the Supplements. If there is any inconsistency between the information in the Prospectus, the Supplements and this prospectus supplement, you should rely on the information in this prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Global Market under the trading symbol &#147;ABIO.&#148; On November&nbsp;21, 2013,
the last reported sale price of our common stock was $1.41 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You
should review carefully the risks and uncertainties described under the heading &#147;Risk Factors&#148; beginning on page 5 of the Prospectus and beginning on page 23 of our quarterly report on Form 10-Q for the quarterly period ended
September&nbsp;30, 2013 before you decide whether to invest in shares of our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is November&nbsp;21, 2013 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): November&nbsp;21, 2013 (November 19, 2013) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November&nbsp;21, 2013, ARCA announced that
Dr.&nbsp;John Zabriskie resigned from the Board of Directors of ARCA biopharma, Inc. (&#147;ARCA&#148;) on November&nbsp;19, 2013. Dr.&nbsp;Zabriskie&#146;s resignation was not the result of any disagreements with the Company relating to its
operations, policies or practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November&nbsp;21, 2013, the ARCA Board of Directors appointed Dr.&nbsp;Raymond
Woosley to the Audit Committee of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A copy of the press release announcing Dr.&nbsp;Zabriskie&#146;s resignation
is attached hereto as Exhibit 99.1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces Resignation from Board of Directors&#148; dated November 21, 2013.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November&nbsp;21, 2013 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">SVP and General Counsel</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces Resignation from Board of Directors&#148; dated November 21, 2013.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g633425g42l43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA ANNOUNCES RESIGNATION FROM BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Westminster, CO, November&nbsp;21, 2013</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that John L. Zabriskie, PhD, has
resigned from the Company&#146;s Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Zabriskie resigned effective November&nbsp;19, 2013. There has been no
disagreement between the Company and Dr.&nbsp;Zabriskie. Dr.&nbsp;Zabriskie has served as a member of ARCA&#146;s board of directors since March 2005. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;I want to express our deep gratitude and appreciation for John&#146;s contributions to ARCA and the Board,&#148; commented Michael
Bristow, MD, PhD, President and CEO of ARCA. &#147;John has been a tremendous asset, sharing his extensive experience and wisdom from a highly successful career in our industry. We will miss his sage advice and steady hand in guiding the
Company.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Zabriskie is Co-Founder and Director of Puretech Ventures, LLC, and the past Chairman of the Board, Chief
Executive Officer and President of NEN Life Science Products, Inc., a supplier of kits for labeling and detection of DNA. Prior to joining NEN Life Science Products in July 1997, Dr.&nbsp;Zabriskie was President and Chief Executive Officer of
Pharmacia and Upjohn Inc. Prior to joining Upjohn in 1994, Dr.&nbsp;Zabriskie was Executive Vice President for Merck&nbsp;&amp; Co., Inc. Dr.&nbsp;Zabriskie received his undergraduate degree in chemistry from Dartmouth College and his Ph.D. in
organic chemistry from the University of Rochester. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g633425g42l43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g633425g42l43.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!K`+(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBL
M[6IVAT\[3C>P0GVY/]*PQ-=4*,JLNBN5"/-)1))=6LXG*F3<1UVC-,&LVA[O
M_P!\US\,1?MDU>CM"P4XX(/YBO"P^/Q]?WDDEZ/_`#.N5&G'<TCK-H.I?_OF
MK%O>V]UD12`D=0>#6#+;%5&1R1G\*IAWMIEE0X*G(J:N:8S#34JJ3CULK/\`
M,%AX27NO4[*BFHV]%;IN`-.KZ5.ZNCB"BN.\=ZO+9Q6UI;.RREA,Y7^%0<+G
MZG^5=1IUXFH:=;W:?=E0-CT/<?G3`LT4UU#HR$D!@1E3@CZ'M7G_`(M:\T&Y
MM_LFJWY2=6)62=FQC'3\Z`/0J*P8?#[-9)NUC5/.*@F07)ZX]/2LGP_X@OH]
M?ET/4Y/.8,R1RD8.1D\^H(%`':455U"_M],L9+NY;;%&.<=2>P'O7+Z9-JWB
MR1[F2XDL=,5MJ)`<-)_P+^9_2@#LJ*QF\+:6R8"3J_\`ST$[[OYUFZ1;7^D>
M*&LKF\FN+6:!F@,CD\@C/![@?SH`ZNBBN<\::FUAHAAB)$]R=B[>H4<L?RX_
M&@#HZ*R/#.H_VIH%M.S9D4>7)Z[EX_48/XUKT`%%%%`!63XA_P"/&+_KJ/Y&
MM:L;Q,VW3HC_`--A_)JX,SM]4J7[&M#^(BG81&0C]W(?]I1TJU%<F6Y=%;:@
M8CCC/;-95A<*'7Y=S=@3@?C5I[64SM+:R(R.Q."<<XR<>U>=0JM4XN"NNMCJ
MG'WG<U)4#ADY8@9^4<D>E8-XI4D%"OL:T0WD0MYK+)(R@[<G[OL?6L2[G4D[
M<@>]9YI4@Z/O#H1?,=M!_P`>\7^X/Y4\D`$D@`=2:9;_`/'M%_N#^58'C;4I
M+'0&M[<YO+]Q:P*#R2W!_3/XD5]#3^!>AP/<S[:Q/B;3-<U`C)O28[3/9(_N
MD>F6'-1?#?5//T^YTYS\]N^]`>NUNOY'^=:=MX*L;>VCA6]U$;%`PEVRKGO@
M#I7%Q8\&?$V.#>WV.XPH9VR2C\9)]F'Z58CUFO./B>^RYTWG^"3^:UZ/7EWQ
M:DV76E^Z2?S6@#M_^$HT.VL4DDU6U("#*I*';IZ#FN=\.:/>ZCXGF\0W<#VU
MN9'>&.089L\#CT`/XU/XO\*PZGX>6ZL;=$OK>,.!&H!D7'*G'4]Q^7>D^'?B
M@:QIO]G7,F;VU7@D\R1]`?J.A_"@"C\3;]DDL;$-A,-*P]3T']?SKN-)M4LM
M(M+9`,1Q*..YQR?Q/-<%\5[*01V&HHI,:EH9#Z9Y7_V:NV\/:E'J_A^RO8V!
MWQ`.!V8<,/S!H`TZ0HI96*@LO0D<BEJM>:A;6'D?:)-IN)E@B&"2SMT%`%FN
M7@C3Q!XBU223YK2UB-C'Z%V'[PCW'2M3Q%JRZ)H%W?L0&C3$8/=SPH_,BL/0
M_!D,>CVS75UJ$=S(@DF$=RR#>W)X'?M^%`&7X!O'T_6]0T.X.'#$J/\`:4X.
M/J.?PKT2O(_%%I_PAGB_3=2MWFD@<B0M*Y9B0<.,GK\I'YUZU'(DL221L&1P
M&5AT(/0T`.HHHH`*S-=LY+W3&2(9D1@ZKZXSQ^1K3HK*O1C7IRI2V:L5"3A)
M270\U6=HF(.01P0:NQ:H5Q\W12H_'/\`C7:3:?9W+[YK6%W_`+S("?SJ/^Q]
M-_Y\H/\`O@5\_2R;$T=(5%;YG<\73EO$XJ74"ZJ,].E-LX)M1NUAB4G)^8]E
M'J:[?^Q]._Y\H/\`O@59AMX;9-D$21KZ(H%#R2M5FO;U/=\@>,BE[BU$E+6]
MHYAA:9XXR4B#`%R!PN3P,].:\]U&U\9:CXJL-8DT*/[+8DF*T-Y'GD<DMG&[
MI[<#ZUZ/6;_:K-KW]EI;D[8_->4L,`=L#Z^N*^E2L>>6[.::>TCEN+9K:5AE
MH6=6*?BI(/X5YKXUT'Q+XKO;::WT(6HMU9-[W<9:0$@CH>`.?SKTZ5S'$[A&
M<JI.U>I]A4=G<-=6D<[020,XR8Y!AE^M`&#H-_XF%N+?6=$Q+%$2+F*YC(E8
M#@%<Y!/KT^E<?XQT/Q;XMNK:5=#2TBMU955KN-F.3R3@X[#BO5:;O3S/+W+O
MQG;GG'KB@#%\/WFN2QI;:OHPM&CB'^D)<(Z2,,#`4'([GTXZUQ.L^"]>TSQF
MNL>&($:)CYNUI%4(Q^\A!(RI]O7'&*]+O+@6=G-<E"PB0N0"!P.O6H]+O'U#
M3H;MXO*\T;@F<X&>/TYH`S;47NO:?<V/B'0UM8W0*P%PLJR?3'((P#S^!KE[
M#P_XF\$WLIT94U;2I6W-:M((Y%]QGC..,CKZ=*]%HH`YK_A*+]HAY?A36#.1
M]UQ&J9_WMW]*QK+2?%6L>,K+5]<@AM+*TW&*U68/M)4@=,Y.<$GVKOJ*`/.?
M%%KXO\1S6:QZ%'!96TPF:&2[C)E(/\6#@#&>.>M=UIMS=W=IYE[8-8S;B/*:
M59./7*\5<HH`\^\>Z7K_`(FB2QL]#"I;S;TNI+J,;Q@C`7.0#P>?2K_A%_%6
MFVEKI>KZ.'@C&Q;N.Y0E$'0,N<G'3BNRHH`****`"BBB@`HHHH`****`&NZQ
MHSN0JJ,DGL*\_2?5)H+G6;:X,$FH72):QA`6E`.`#GHH&>G7%=Y=6Z7EG/;2
M%@DT;1L5.#@C!Q5#3=!@T[R6::6YD@3RX6FQ^Z7IA0``/<]3ZT`5O%-[>VUK
M;P6$JQW%U*(DP,L2?3T&,Y/;CUS4FLZA<V4=C86SJ;Z\?RDD8<*`/F?'?'I4
MNH:!;:GJ=O>7,DQ$"%1"&PC9ZY[\]#ZCBIM0TM+^:VG$TD%Q;%C%+&`2-R[2
M,$$=/Y4`4M"O)IM1U6T::2>"TD1(Y9,;BVWYP2/0C]:YJZNKPIJWB".\9)H)
MUM;?RE&V0!@",'.1SGZ@UOZE-9>$?#-P()`DA5C'YCY>64\;CZG)!--T+P[#
M%IFG&:YDN$A`F2+*F,2GDMP/FP2<9/%`#O%US,NA):0KFZOI%A5!UYY/\L?C
M3-.-_:^)DT][HRP)9!Y(P@"1'=A57OT'?DUJWVD17]U#<O--'+#'(D10@!"X
MP6''WAVI^G:;'I\;XEDGFD(,L\IR[X&!D^PH`R-7U]HK6]FMIA#!;$Q"3:&:
M6;^XH/&!W./7'3-3S2WVE^$6GGN<W<<.^25QD@GG`'3/856/@FR:*-&O;TB*
M?SDS(/E.<D`8QR>_6M:^T:UO]-33Y-Z6RE3LC.-P4Y"G.>./K0!F^'H-9GMK
M*^O]1?:4)-L8Q\P/W23Z]_R]ZSK_`%C4AKU^L=ZL5C90DSLB@A,_=`R.7/'7
M@$GCCGL\8&!6(?"]BUD;5Y;AHWN?M4Q+#,S9SAN.1[#'2@#!TF^URXO-(MYK
MQ_,=3/+'M'$.>"Y]3T'IQWKI=0U,QW1LX'1)%C,T\S\K!'ZGU)[#\?JD6@VT
M>MSZJTDLDTNW".?D3`P,#_/6JU_X5M=0O+VXENKI?M:*KQH^%^48!QCG'H>,
MT`.\,3W5[9SW]Q<2RQSRG[.)``1&.`<``9-;E4],TV#2K)+6#<54#+.<LQ``
MR?P`'X5<H`****`"BBB@`HHHH`****`"BBB@`HHHH`:\:28WHK8Z9&:555%"
MJH51T`&*6B@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
FHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g633427g95w33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g633427g95w33.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X0OR17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P(#<N,``R,#$S.C`U.C(S(#$R.C4X
M.C,R``````.@`0`#`````?__``"@`@`$`````0```*V@`P`$`````0```#L`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```*Q`````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"P`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`.OR^I9N7D.;18^JII+:VUF'&/;N<6^YSG?2V)ZZ\YXW
M#)N@M<[^<=^;]+NH85;'..\-VR3)=M[^*TF7SE64[MC*R`XP)<Z/<]ZP,499
MC[N7)*YRX0`?\+_!BW)$1],8C0.9;]OKXR;I`!/Z1VD\2M7HO4+LNNRN_P!U
MM)'OXW-,Q/\`*]JCEBJRLF0?<1JX-:2/SS^<]R%T(1DY/'T6<?%RGP">'FX0
MCD,L>2[!/%^A*<?^BMF1/$20`8NTL#ZQ_6AG1<WIN*0TC+N_67.G]'C_`,T;
MM/HN]>RK_K;+UOG03QYKSSJ;^F]>Z-UGJ%F90,K*L#NG4OM:'#'P]U=+/3<[
M>W[9^N7_`/H4MAJOH86+]8^I=:Z5CV]0Q*L;(P\>O?=5:Y[+=#[W5O:'U.:U
MNW]'L3_5'JO[5Z!BY#B3<QOH7SSZE?L+C_QC=EO]M+ZY?^)?J?\`X7<DII]+
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MZ[O_`$(7=`0$E//=.ZOU]G7?V/UK'QV-MH??BY>,7[+/3=6U]>R[=LL8VW])
M7O70]E!U%3[&6O8UUE4FMY`+F[AM?L=^;N:JO6.IU=)Z7E=1N&YF+67[.-SA
M_-U`_O6V;:TE.;5]9V6?6ZSH$-])E(+;1.XY`_36T3.S8W&<QW_&>HN@7F?6
MF8_2\#HO4L7-HS.J=/N=9G^E8U[[+,AWVK)=MK=N<SU_5I_XJ]>CXM]6317D
MTNWU7-;96[Q:X;V'_-*2G__0ZG&N--S@3L<U[@3`)!!.FOYRT''$R(LL!;;M
M<=S7D.+6CV-M=^<]_P"\KF9T;%R[#:2ZJP_2<P\_UFF6H(^K]0_[46^'YO\`
MY%8T>2YK$90C&.7'=QXC'\I?+)M'+CE1LQE36R,MC*O3J]C`/:.Q!UA^[=^E
M;_I%/ZODNNRG@0V&#3B?<Y%/U>H)UOM/^;_Y%:&+B4XM0II;M8-3K))/+G._
M.<I>7Y7F#S$<N7AA''?#&)O>/!P_U8^I;/)CX#&-DRW+A?73K-6)TX=-JR64
MYW5'MQ*BYP!K9:15D91_<934Y_O_`-+Z:U\;IO3<?'JIIHJ%5#&UU^UIAK!L
M;[X_="%D87169`]7"I??FO+7.]%KB\QN=ZK]OYK&_GH]E73\+`=6:F5X5;"U
MU+&2S8[Z;?1K:?:[=]'8M1KO%?5?J&'T'ZT=3Z%=DU-QK[=V*XO&T6?393NG
M:VQV/8RK^OC+H?KMDXU7U7Z@+;6,]2DLKW.`W.<88UG[SGK1;T7HHJ](8&,*
MR/H>BS;']7:G=TCI#G5N=A8[G4,%=+C4P[&-G;77+?8QN[Z+4E/._5G$Z;UO
MZD4],ML99(L:_807U6"VQ]=FWZ3+*O99_P"HU4^I_77](R;?JMURUE%N*[;A
MV/<&M(Y;CL<__!O;^FPO^"_5_P#`KKF].Z5BVNS*\2FJYC3-S*FA^V/<W<QN
M_P#-41B]+ZC6S+MQ:KO6K`:^ZII<6?28T^H"[9KNV)*>3ZI5?]5_K0?K&RMU
MW1\X%N<^L;C47[=[W!N[V>K77>Q__'5?Z)=GAYF+FX[,G#N9D46"66UN#FG^
MTU2IQ\:BEN/16RJE@VLJ8`U@'[K6-]JH6?5CZO6/=:<"AKG&7EC0S<?%XJV;
MW?UDE-;-^LM`ZWA=#Z?;5?G7V%V4V=PIHK:ZRTOV.]N19M;737_UQ4^L9V%U
M7ZR=.Z"W(J=5C.=GY]>YON=3_0\3GW/]=_VFRK_1T+>Q^E],Q6;,7$HH;!$5
MUM8(=]/Z#1]-#_870_2%7[/Q?3!D,]%D3XQM24BZQTC`S>F96(YE5'KUN:+=
MK6[7?399NT^B\;U@?XN?K!C9/2ATNZ^L9>&3Z=>\;G4GWM<S7WMI?OI]OT&>
MFNLRL/#S*_2RZ:\BK<'>G:T/;N'T7;7RU!?T7H]@:'X.,\-U;-3#']7VI*?_
MT?54DDDE*3&4Z8QW24XN;=;=F7.H<6NQVG&QML%[KWAMEFT/W-;76STO6L=^
M9ZBM9=]PR<7%KMV6O(?:0!]!D;_I;OYU_P"B8W;_`.>U:9]E^T6>GZ?VB!ZF
MW;ZD?F^I^?\`YRE^@]8?0];;IQOV3_G>GN24YG4<[(%N2VE_IG'#&4,;&ZW(
MM]U;=?\`!,;^;_QO^B1.IN%M^/BOL].H!V3DD&"UE.TL=N_X\L5X_9O7;NV?
M:-IVS'J;>^W\_8J%?H_M3*^V^GN_0_9]\1L]^ST]_P#A/7]3<DI%;?EOZ'57
M<3]LS0*1(#3#Y<Y]@;_-[,4>I;^XCT9!H.9<^POPL=C-I`$;FM+KA1M_P>WT
MF?\`&;U=M]#3UMG?;OCP/J;=W\CZ:8?9?LFGI_9=FGT?3V1_VWZ>U)31Q\J[
M)Z@RKU0&U--EU;(+=SA^AQ]_TK/39NLNL^A_-IZCEY67E!F0:\>E[:V.8&ZO
M9[[F-WAWL_P5O\M7:OLVX^CLW0W=LB=L?HOH?F?Z-$K]/;^CV[9/T8B9]_T?
MY?TDE.3GYUS,FT4V'T:&;',8!+K[8&/CU;MWZ?\`/=_HV(G3K\AUUHOR!8W&
MK;7=`&TW-]USV?G[:_H?\)8KWZM/^#G?_)_G8_\`/JE5]GA_H[(W'U-D?3_/
M]3;^?^\DIS&=0MR\G'KJM%3+2+G-:02*1_-->[7]-E/_`#&?S-2UP(0*/L4M
M^S^E.WV>GM^A/YNW_![U824__]G_[1"*4&AO=&]S:&]P(#,N,``X0DE-!"4`
M`````!``````````````````````.$))30/M```````0`2P````!``$!+```
M``$``3A"24T$)@``````#@`````````````_@```.$))300-```````$````
M'CA"24T$&0``````!````!XX0DE-`_,```````D```````````$`.$))300*
M```````!```X0DE-)Q````````H``0`````````!.$))30/U``````!(`"]F
M9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&
M```````!`#4````!`"T````&```````!.$))30/X``````!P``#_________
M____________________`^@`````_____________________________P/H
M`````/____________________________\#Z`````#_________________
M____________`^@``#A"24T$"```````$`````$```)````"0``````X0DE-
M!!X```````0`````.$))300:``````-%````!@``````````````.P```*T`
M```(`&D`;0!A`&<`90`P`#``-`````$``````````````````````````0``
M````````````K0```#L``````````````````````0``````````````````
M```````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````
M````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````````
M``!"=&]M;&]N9P```#L`````4F=H=&QO;F<```"M````!G-L:6-E<U9L3',`
M```!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````
M````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R
M:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y
M<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$````
M`%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<````[
M`````%)G:'1L;VYG````K0````-U<FQ415A4`````0```````&YU;&Q415A4
M`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!````
M```.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!````
M```):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L
M=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A
M=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90``
M``!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG
M``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO
M;F<``````#A"24T$$0```````0$`.$))3004```````$`````3A"24T$#```
M```*X`````$```"`````+````8```$(````*Q``8``'_V/_@`!!*1DE&``$"
M`0!(`$@``/_M``Q!9&]B95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`#`@(
M"`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1
M$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`+`"`
M`P$B``(1`0,1`?_=``0`"/_$`3\```$%`0$!`0$!``````````,``0($!08'
M"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&
M"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3
M\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2E
MM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%
M-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&
M%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`Z_+ZEFY>0YM%
MCZJFDMK;68<8]NYQ;[G.=]+8GKKSGC<,FZ"USOYQWYOTNZAA5L<X[PW;),EV
MWOXK29?.593NV,K(#C`ESH]SWK`Q1EF/NY<DKG+A`!_PO\&+<D1'TQB-`YEO
MV^OC)ND`$_I':3Q*U>B]0NRZ[*[_`'6TD>_C<TS$_P`KVJ.6*K*R9!]Q&K@U
MI(_//YSW(70A&3D\?19Q\7*?`)X>;A".0RQY+L$\7Z$IQ_Z*V9$\1)`!B[2P
M/K']:&=%S>FXI#2,N[]9<Z?T>/\`S1NT^B[U[*O^MLO6^=!/'FO/.IOZ;U[H
MW6>H69E`RLJP.Z=2^UH<,?#W5TL]-SM[?MGZY?\`^A2V&J^AA8OUCZEUKI6/
M;U#$JQLC#QZ]]U5KGLMT/O=6]H?4YK6[?T>Q/]4>J_M7H&+D.)-S&^A?//J5
M^PN/_&-V6_VTOKE_XE^I_P#A=R2FGTOJOUKZMT^OJ.-3T^JJ[=Z55C[BXAKG
M5^^UE>VKW,_T=RL?5SZT,ZS;DX=^.["ZCA$C(QG.#QH36Y]-S=OJ-;8W:[VK
M&^K_`-:NE=$^JV$W/]=I:+=A;38YECO4L?Z=%^S[.]^W_A5=^JG0<RCJ&;U_
MJ&RK(ZF7&K%K>+!74]_K?I+F?H[K715_-?H_^W$E.EU_ZRX?16U5O8_*S<H[
M<7"H$VV$^WO[:Z]SOIO0ZA]<,AGJV68'3W'5N,*[<HM_D6Y/KX3'._>]*E8'
M0IZE_C"ZGE9/N=@MLKQP?S0QPQ6;?['KN_\`0A=T!`24\]T[J_7V==_8_6L?
M'8VVA]^+EXQ?LL]-U;7U[+MVRQC;?TE>]=#V4'45/L9:]C7652:WD`N;N&U^
MQWYNYJJ]8ZG5TGI>5U&X;F8M9?LXW.'\W4#^];9MK24YM7UG99];K.@0WTF4
M@MM$[CD#]-;1,[-C<9S'?\9ZBZ!>9]:9C]+P.B]2Q<VC,ZIT^YUF?Z5C7OLL
MR'?:LEVVMVYS/7]6G_BKUZ/BWU9-%>32[?5<UME;O%KAO8?\TI*?_]#J<:XT
MW.!.QS7N!,`D$$Z:_G+0<<3(BRP%MNUQW->0XM:/8VUWYSW_`+RN9G1L7+L-
MI+JK#])S#S_6:9:@CZOU#_M1;X?F_P#D5C1Y+FL1E",8Y<=W'B,?RE\LFT<N
M.5&S&5-;(RV,J].KV,`]H[$'6'[MWZ5O^D4_J^2Z[*>!#88-.)]SD4_5Z@G6
M^T_YO_D5H8N)3BU"FENU@U.LDD\N<[\YREY?E>8/,1RY>&$<=\,8F]X\'#_5
MCZEL\F/@,8V3+<N%]=.LU8G3ATVK)93G=4>W$J+G`&MEI%61E']QE-3G^_\`
MTOIK7QNF]-Q\>JFFBH54,;77[6F&L&QOOC]T(61A=%9D#U<*E]^:\M<[T6N+
MS&YWJOV_FL;^>CV5=/PL!U9J97A5L+74L9+-COIM]&MI]KMWT=BU&N\5]5^H
M8?0?K1U/H5V34W&OMW8KB\;19]-E.Z=K;'8]C*OZ^,NA^NV3C5?5?J`MM8SU
M*2RO<X#<YQAC6?O.>M%O1>BBKTA@8PK(^AZ+-L?U=J=W2.D.=6YV%CN=0P5T
MN-3#L8V=M=<M]C&[OHM24\[]6<3IO6_J13TRVQEDBQK]A!?58+;'UV;?I,LJ
M]EG_`*C53ZG]=?TC)M^JW7+646XKMN'8]P:TCEN.QS_\&]OZ;"_X+]7_`,"N
MN;T[I6+:[,KQ*:KF-,W,J:'[8]S=S&[_`,U1&+TOJ-;,NW%JN]:L!K[JFEQ9
M])C3Z@+MFN[8DIY/JE5_U7^M!^L;*W7='S@6YSZQN-1?MWO<&[O9ZM==['_\
M=5_HEV>'F8N;CLR<.YF118)9;6X.:?[35*G'QJ*6X]%;*J6#:RI@#6`?NM8W
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M:[':<;&VP7NO>&V6;0_<UM=;/2]:QWYGJ*UEWW#)Q<6NW9:\A]I`'T&1O^EN
M_G7_`*)C=O\`Y[5IGV7[19Z?I_:('J;=OJ1^;ZGY_P#G*7Z#UA]#UMNG&_9/
M^=Z>Y)3F=1SL@6Y+:7^F<<,90QL;K<BWW5MU_P`$QOYO_&_Z)$ZFX6WX^*^S
MTZ@'9.208+64[2QV[_CRQ7C]F]=N[9]HVG;,>IM[[?S]BH5^C^U,K[;Z>[]#
M]GWQ&SW[/3W_`.$]?U-R2D5M^6_H=5=Q/VS-`I$@-,/ESGV!O\WLQ1ZEO[B/
M1D&@YES["_"QV,VD`1N:TNN%&W_![?29_P`9O5VWT-/6V=]N^/`^IMW?R/II
MA]E^R:>G]EV:?1]/9'_;?I[4E-''RKLGJ#*O5`;4TV75L@MW.'Z''W_2L]-F
MZRZSZ'\VGJ.7E9>4&9!KQZ7MK8Y@;J]GON8W>'>S_!6_RU=J^S;CZ.S=#=VR
M)VQ^B^A^9_HT2OT]OZ/;MD_1B)GW_1_E_224Y.?G7,R;138?1H9L<Q@$NOM@
M8^/5NW?I_P`]W^C8B=.OR'76B_(%C<:MM=T`;3<WW7/9^?MK^A_PEBO?JT_X
M.=_\G^=C_P`^J57V>'^CLC<?4V1]/\_U-OY_[R2G,9U"W+R<>NJT5,M(N<UI
M!(I'\TU[M?TV4_\`,9_,U+7`A`H^Q2W[/Z4[?9Z>WZ$_F[?\'O5A)3__V3A"
M24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H
M`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``W`"X`
M,`````$`.$))300&```````'``@!`0`!`0#_X1)(:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X])^^[OR<@:60])U<U33!-
M<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@H\/V%D;V)E+7AA<"UF:6QT97)S(&5S
M8STB0U(B/SX*/'@Z>&%P;65T82!X;6QN<SIX/2=A9&]B93IN<SIM971A+R<@
M>#IX87!T:STG6$U0('1O;VQK:70@,BXX+C(M,S,L(&9R86UE=V]R:R`Q+C4G
M/@H\<F1F.E)$1B!X;6QN<SIR9&8])VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N861O
M8F4N8V]M+VE8+S$N,"\G/@H*(#QR9&8Z1&5S8W)I<'1I;VX@86)O=70])W5U
M:60Z,#$Y.6-E,#`M8S,V.2TQ,64R+3@W9C4M.#<P-3`Q.68Q,CAF)PH@('AM
M;&YS.GAA<$U-/2=H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO)SX*
M("`\>&%P34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W`Z,#$Y
M.6-D9F4M8S,V.2TQ,64R+3@W9C4M.#<P-3`Q.68Q,CAF/"]X87!-33I$;V-U
M;65N=$E$/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX
M87!M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*/#]X<&%C:V5T(&5N9#TG=R<_/O_N`"%!9&]B90!D0`````$#
M`!`#`@,&````````````````_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!
M`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P/_P@`1"``[`*T#`1$``A$!`Q$!_\0`X@```0,%
M`0$`````````````"`<)"@`"!`4&`P$!``,``@,!`0$````````````!`@<(
M`P4&"0H$$``!`0@"`0(%`P0#```````!`@`1`P0%!@<($@DA,3(0($$B$T(4
M"B,6%Q@5-QD1``$$`0,#`@0#!`<%"0````(!`P0%!A$2!P`A$S$((C(4%4%1
M%F%"(PD0@5(S0R07('&"4QB1H6(T1"4U)AD2``$#`@0#!08%`@4%``````$1
M(0(`,4%1$@-A<03P@9$B!:&QP3(3!A#1X10'(&+Q0G(C%5*",R0T_]H`#`,!
M`0(1`Q$```"4I\O=@QPT\R-U/KNJY/S?<G3]#<&.$[UXENL;H;<01KV,HI*<
M/LVW/1!6,<$A\3>S)[9C=S'%$[Q1R_SA[S'W]#L$JQE#S2#Z^>V0+"OMWS?N
M/J1Y\BA8BDF#<*E1@P>UY"*Y%2Q28YB)9M-("<4I0F09$YL5)<)(_GY\-RS,
MW;P]73]BH&5?,"#IQE1Z[[=ZK-G6"Y2;DER\1QAT>%M2T$,+C0?D1YBM&R@"
M=N$C5R5@CA?G$WH,G;;$BG9;\T/FMWO>3ZKM'LON?J+'?MR+(<+IS+=;CC2W
MJ+48B"572C;#ES`-((#3"F%(''"-2F1,1[3[(POZMY*W/-_/ISE-3=W$7=9_
M\>.M!CT"(CLT<63USKNQ\.I7YL%A=;-*XXX>J))(9@T*1X%?$?!6BNIZ<;<2
M"AL[5/,$/0$L`).G`%/!JN*:[TE-G2FR8#2F-]+*H*"@H+`%H>M9I$;,-FT*
M<HG0P2M0UUY.,/8#'X9`"%BDZ;#R&4%!04%!B$VC^<<67R#=5*7,**IN9\;J
M3-'C"\RO1QC4;2;N9__:``@!`@`!!0#9G;RZI&[J-F'/]PLN\]BER47,^?J)
M4]3]J*GET0RI2&"@WT;DAB]O<2'-X8E)'(!@H'X$D,]_PD*/-7-<^-,:RU-I
M%#I&/+ID<P8BF1,:RTN-2-FX;F\O4$D'DH^2RR2B)R_)Q4IG.;PIO1@HH+WL
M`>1!0%.'PQO^RF+OS/(U:X,+V+L#(4JS\KKA3MG:\QI1.U*%<D\0HAR2GQ\%
M?:E15R*F'W@$K3\220$\620`U9D:]9M[XGS2955(RW82)?*.8C7X.JD.JUC8
MX)+OQ\P`'KXO4.`5#*T+>5$I0D@ACX400Q#F/Y%$%[`$AQ"N/G/NI-G9CJ$I
MU_Y5IS'0++R9977WDN:F,$Z_6K@FBPP4A2#Q\%GN9("64A)+@YZP>*63]K$!
MBEX`<P\-ZM^EP8@%BA)8)2&XI^!#PK@00@%Y?ZGB4,04D/47,\+9Z&<R>)/E
MZ@X?7Y@7GT8E+@H!B5$$I!24LH)*>7@KY@EDI+@M$0`@CDA:O"A\Q]/JESE>
MV'[DM$]#ZE[E.XI]JO6+ZK<_]2?:W__:``@!`P`!!0#'6*Y>?D)B@V'`'_'X
M_,66M6Q9^%D+'42W!X>Q>"0WT/@EP8^]@`6\%AQ4WEWE[R$GU:ISG[60J];B
MQHD>=K$G'MZYX<Q&R'&C3>/_`+RD/+`D`I4\A0+@IB`Q'CT90>/M42'MX8@L
M0H%Q!:OH7&IEN*E/[IK5F3IFZ"J&FH7C_2Q\"7!7$\@"2%?#T8$.+G@!:3R+
M$O/H7!X<\/2Q</A(IE*S1KBM>),K51[AF$VM;ADXN3#+4NR$EX3S*7DL2D'S
MR2A3B?`XH4'A@D<?KY`<]2CX^]AS#?C/&S,C5&U1$S=0YE1S%;G,9MHT(77>
M=0NV9Y+#*2]O#@H@CP>'%AS>/#!X`*P?5B>3$<F)420])>]Q>WHQ#VX@,X/>
MYOL?Z'R5)>I@$A"@"SG$`ACZN\^0SGJ#B04N\/\`E>`/U%2@KRP47%RF"DD$
M`$H2D``,X`'U#DD$)8<7D*4P!'S_`%'M;PT-HGN5ZCT_6&#!W.'Z#VAWQ__:
M``@!`0`!!0#97<2]5W91LC[%UU,6Y-B8-.JN5-BK=GM3]KZUDZJ0XB8B5+2@
M;H=AV.--K_EXBUIKLQ496FYT[IIK5.I8[[+L\YCLG63M@UMV(RFB:A*A[=]@
M.LNDU(MS<SL)R_1<\=PNP6FZL<7M)Y'LJ.KA"R)V#V%C_?B$28;6O08];N2Q
M\>T^BR-%H=D5BG9-Q/%DI37:E(I>RTL_BN+`1$[*K&NK=;%G5_LHO:;2;[EM
M_)J@0H&$]!@B)HSW54B?G.V?;?8BE:I:T=)^OU9W&SS!E5?CS[A*P=B<2:Z8
MRJV%L(7[?%O6!8V[%BYPAV!@'--`V#PVV.(E/%P9;DZF<0V+GVF25OW\F-/6
MCA68DH^S4%P':[L/<FO^I5DVOL-:.F?0#E2[\![+P5`H_DTKAC"=TW5VD:T]
M9O1Q3=8,\6YWV4:HU/K?_CQ52A36@X``*(:F7P$/N2R#>MW6;NO1MGMI=.OX
MYVRT:]L+M"FJC9MYXLR[)TB)*9!L6E)R9E!%:A:R352N?9*J5.GTR4I6Q>(M
MZ.YQ4>6BPNVB>H6FW:[@K8G"VQN//Y+>4,?5JQ^N?(.*\FZ'["V%DKI([$*1
MD/53L3UJU2OO+?1=M/CW(-DY-M?<+>77;2FPNN3.MU7AIGUU9BQWO%V/S=0E
MY:'4<LX]ZP>[+_/6%?\`'&?=1K9S'4I'0K+DC#_T@S!^VC:"Y2G)G`>M]HX(
MIN7L'8GSO;,WU^=?E6"+6HDI0*)UP:'4HV'HUJ1BN[:'UPZ$4!=AZ-ZB8ER!
ME3">"=B:%:6B^H5A7W>F.['R10%=3^CTG.6CUE:+6?4\@:>ZQY5H\+KRTDE:
MY?>.;/R;9],ZZ-%J/+_^8F@)AE(4`D!E0T*;\,,-P3RKL_)TFGZR9*L>BU;/
MF2,<46T*K<-DX*Q]8F4:5?4Q>NU!M?*L_?MN(L#5C)5CXIQ[<-UT6T*7969Z
M3?-WU;:['%*KM=S+;-M6'+;<XPFIW&F7J)E:F9&SO9.,Z?0*S,5JB?*L`C;6
M1O"JX6L7%\6MUZ_K=OZ^=C\ZVU5XN6,(6=7[,AV#(WYEG%F;\>7%.89M^RYK
M)-P9)J&649NU4M:ZK5QSKQC2MR=U;'VK>F3C6[$R-3H]@VI>&)]=?[+RI<DO
M*_E,O\T=SCPY)<Z$[GMW^]_U[Q!_U(GB^#Q_-%]Y]L)SH_%E._(GVK?S1[6_
M_]H`"`$"`@8_`)_QY_%4HPZ*&V1O=;MR,9G=BJQV]P@)$$>4P\TB$\PD!75#
MTS^5ON4[NUN&$HRWY@GS`$CRH3DA*@J@N.DZO:_E;[CC]><H1_\`:DA(0I%1
M>,2#)18A*_;=3_*7W'/=V"28[G4(#H-CY=.DR0'4A<9UUOVI_('1['0_>O3R
M$=@`3'[C;`^:6HGSE!J>(,D15:)F$DCT!0*,2BEAB^9"HJ9WH9IV/?0R]O=A
M4M1D`H"Z3C:V.8]IH(FDGLSH.:4=(*`.S^'#L:>U+J`#N5RX>-!))+B,.8)Q
MH:@CI^N#63-<Q1$7`4+Q7ADX/$5QH`1!!!0V<<'/'EG2]O;^&[L;/6RV]W]Y
MN@&$D*?5W`-9D4E$8Q`&E`48FNN^Z/4);/1]7MG8CN;F[*(Z?=V9[D82&V`1
M$;WT]>V92^I&2DG2:].CZ/TW5;/I'HW5[T]C<WXZ]K?*Z80.]$E!$`&32U@V
MBAKU[K?1_3R?3.HA(;_4RE&&SM@G4/H*GU$7S'&8E81$C]@='U?6;?5?5._`
MR<D?3Z?=G`Q<!`\2H(.HD&U%(H[\\>V(>HH/T-;BC40`0>(8]L0UJ!C\I?VN
M/U'<$JX0^[\ZE(D!`<%[EP7ABCW-;FB0N?>?;FK,@2H21))X/@R%\"@XVHG4
M3C\51O"R-1D81,UY`A;_`)-\"&I0%).?YV]F=Z^8D\0A[>^]`(W;QH3B"9A%
M)<HSE$#NH`1+)11_RSR/X=>-OTV?4]1'J.H)CK$=0COSD(ZRD8D(7(?)2*^C
MTGIW[3>]*ZO]YU?1=-OCJ>LW.G$2-V6YMP^4!3.`!$IA$21*SZ'[?Z7;ZOT_
MK_I?LND"RZF6[,1VY#J=HPB8QD%.J(),SITY;7I7J'3#KMSINC$NHZ;]W*&Y
MTLI/&$^F*3(*QTS4H`"D=-?QSM]#Z?/9@)=1%3(2'_Q[C6,@9`,#(NCR1:C(
M_,@7P6@-`+H7(/`!'O@J(O*M1OPMX`I3&106.91?`E"Y"\/P)U:7#Y*;X67N
MJ<-,#,&[C$N706R(OWK*8$@$?!410W!,^^I1$E*&P4W2WL3.HR`-D=RHNI4J
MG#^B41'!CQX^^XX&OIAU0<#\?>U$!?*Q[RRHH!X$L._\.M]+Z_:_X_U"/5[Q
MGM2.G<TG>,XR"A2#$`A'*ZDKHO1=SU7:CTNQ_O=9O_2D.JZJ&W+7#II%9@[>
MX2("(.E=2Q)->E?=73?;_I'0=7UG4]3'>GT_3;<=W8VC`?1EM[B1EMS@9F:0
MB"9`JYKZ'J_3D^L]#.<.DW]J1.[U$5($^NGN`R.X(@%1(8H`@K[$]2ATXW>B
MZ4[QW=R(U"!ELRBDI.`!-B2LG9`3($&/#LY]IJ<;@%PYN5Y7O>@@0_F]0.E9
M#!!8"ZX!E`'AG*4B$`NK`)^5&!*DCER<V=!V-:C%C(\G^)7WUY8CZ974Z*6`
M(&)P`RS2B6E!39VRYY^ZH-(BP*EK+JPP"')>*VI2P[6S-!-M`AX<K8)GSH(X
M`/$\3GX`"HZ4)6^(5_904#3B@Q1%*)_B;(]+I_N_7PJ?W;Z?N?\`'?R(-N`'
M4`+ME%_\L`ADH!!,7D@U`W'4'T_^2/2(1W)G4);6^9'%5AI"$N(N0<PE;711
M_EKT8=-MS,P3L=60J(FE5"C&+A.(KI^I]6_E#TS=V82(G"&SU!E.)(B$^IY5
M$5340$*,B'JO3/0Q+>ZKJYG<W=V86>N5P))Y1$,`,.0HG$AUQYAPS/0.F]V\
M7;*K/6E&3+CCWWH@!DMAX4L@ZK4D:C+0Y7ED`]FR'.@@M00E<\;)008`=PH@
MR)"K<M:Q"'#/,6-!72V)3`$E2>^]`BX_P\.%J"X$$'%1CSXT8?Y%5,*X4<#0
M4*E!!:G&"=WX,B\;<N"YX<;49F7FT@D!3BS!S[N5+.41`8DLH\+7+MC4C+]>
M)R3$>ZAI0W\1V>I&94($#KC<_##OHA40]D3V5.,B!)2@56N"695L>#T3XO89
M^&%`[9B0I=<B0?=1\RE<`4"G.Q[J)-N8?@'OPHQO*Z(;.A.2H>>%/%&Q;XJV
M9"9*AHHAFB@$H#D%M>B"$[=OS_KD5\P!3$>_O;S,@2B(D2*8,%OS\3B]:MR,
M5.&2LQ+*5/$^%2$BZY'(65OUXT(D^3PX+P5??B:B%*RLB8<7PS1<*,Q$ZG('
M,\4NCXUI.V$-P"PLHP7G9L:((,1PQ/%"J9L1[J%U140^W/(<`*TB-BG@RCN4
MMWUJ2.K/L5M9*6&L$EQ9TLA8868FX+F@`2B$DI=\,ERI-1=;8LK8)SQM0*,Q
M^/\`6+8>^A3+A9<L5P_17H_'XUWE<OE]_+A4;*G^7Y;T%2^/P3'.HWN;]O?6
M*(>V?@]&Z-GP[Z"5'L</9GW5%>-[VP3X8+0_U"_:_LH_Z>_&_#]:"63\/__:
M``@!`P(&/P#_`)SUV#1(,=N::#'2J2642I'O".143/[8Z**$0/\`M^4R2\2I
M421B+G4!C6]MR^W>B.F`)TPL#8MB70BP%;?T/M[HXC<"`F#N$4*;@*04+^8@
MD"CZAT2CTG5>Y#B)):PDF;2".H!`_"((`!**50%%]N'&F'ESXT34G"#W*@/,
MY*2&S%(HLJX70AE*BZ(AP-"`B5:V-_"V(0V!)5%PH.`./;F65GPK2%,D"$!1
MSN%M9K@BB`H=%(YV1<KE`EZB3%%=,0V-Q[2ZB@RT"0V>?C:V3JC4?PZ/<V8K
MM1V8*(Q#Q&W$,(D^4.2(^8HK>85O>G>E'ZL=V)T#S:MN<7)`&DB#&0!`T+B3
M6Y#J-V,MW>VXQF-7FB(W8_-J<`@AB]ZE#?WI0A`IM[,01,E`0\7=!$(D0Y-G
MZR?41D=V&T$14&F<1I)()'FD2`JG2<*B9D*7M@W;L[&WL[)1&@JI)$2-1_M*
ML$8EP>*/4I2'F-D).-[977.D(2@"P6XNN!`0JZ78?,02*),G>P[-AG4R-QP0
MEV="$%P197B2995+LZL`J+P+7R>H_5`!5@'$0CC4KE27``0@`%:<#05L'?B?
MR[G-$10A'9U<X7S7#PI1\IR;$X<^=DY(VH.E^QQHRCM>:,B2Y)(90&(4D6=4
M0$4A*!0Y_(%>;-^'3[W[L[</I0RD^F+G48@EF?R@HF-#_DNHU1G`QC.<-,=8
MDH,9+'49`7*@6#H:W^IW(:>FVTF9`J$S$K.'<C%61=Z73]:-G7(I_MJ)Q-SJ
MLY%BC@XUUVWN]0=R4XA%`!(!4DI+!'0%$L`2:1?*K4";H4=!WETNMEI2)'<=
M@&)']VH,;`G"],3I0D+FI4-<`$(`H12<*!1B.QH3)$91*_*2C$*@?'`@G`HM
M1BBSL2"`'(6ZE."KWEMN4M)W"+H0F!`4*`%0J!(A!+!)1(4)R%P+AP,5#]U&
M1D9$C%BF!(0:>7.U$XTJO2$6XIV_.HOY2QP*$(2OP1:C`"3@.BBX4%P7NJ/X
MBC$"1DF+LR$D-P3,69?PVNJZ*4-[IQ&`U)%I:`=.`!U*X&:W4]7U.]M?4ZMX
M0PAMDOJS4`J3\H%;_I,O5.IW.EV-N$H1G.6F114(*?,(H['RA!7[L=.8[&X!
MJBORF\?IBR$L8EHDJ%(%=9TLC].>[`&$5"D*%:Y8V8-BB5`]^++W+9V%:8Z0
MB<25BS!XX%U7FM9CX6;@5R=#4#-"^5LSJ%L%!8W))K005)<!%4J?@R^ZM6KR
MJ"2J``/<@C($9$H012ZFSPLM^.'C0U(`3PL`9$E;J5)0*AQO4)*NH>(.2W"=
MDJ$2?*#I`1!B@S)`*70Z5`5:*A"@./<!W.X!-$J@N]@&<J+8LI7!JT;8!3$.
M<%5N+U)OE4'-5#\D((X7RK0(H01S4!^^_):4&(_[7NWFS_MP"D7-?(Z=UD7D
MKY5N0^B=[HBQBKB)N@((OX%$+"AN]3Z',[B(`@`#`?*59&))<]]'=CZ%O?7(
M`)\KBZ6SXVJ>GT;>73Y7"`WM8#@`"KK7U^IC';Z:+"`54%KD$D+=A=;FB1D,
M<K7]H%)(%6NV#.;<+$&ST6N>[(-WUQ("M=%OF`24!/=2NO:_+W-:@`$B,`P"
M\F?VO1()*A"%*7YI[+-:G(0)AXMBF.8J0"/?P3V(`,@PM0(E;AD5'8TI'FSQ
MNM_SH$_.%0\[]R?`X4DP"'NF*+A8H&LUJU&7FSQ3)<LA872DD5NV!!"?H1:B
M04)Q#9!T3``<FI5-\SV[K8W_`*&I<:O9^'/F,,:,X3'TU8JBX&[J`EQP5;1&
ME00>YL78%0AS#&I>1S@,^`QS[EL].`K*EQ^I#A:E(JH<YID,WR4W04=40#D3
MP0V\5[@M:9H9`E(OS<W1,5"*Z8Q!3W,B9X4B8X(6"8J@5THB9TRN>`0EL26L
M%KV(;@XA,3B!@X-2CP8^\E"2$;/@ZUY0=.!(0&P8V(Q9P;A*CJ(5<P.SE$NH
M8WI"0GY^]'']144)3@3*P"A5[^;$MRO3+J(3#EE_TA%7E>E)"$V?@N/@J\,:
M-D7X(W%,^"(:$57!+=^3<;9I4I[2(C%!=&D%75G>X8`4R$@_!0I6RORP5JB@
M'('@G$$9!0B"@2J(M[DG2A9B+_Z5.%!``$3+CWI[4HGP=V*6L!EF%>A)T_0N
M;8DG,-1B`I5LGY(75R3W*'B`?+R$5\JE0,2ZIBB5,Z0I'BM@1=K(22I#C!RI
M_K/;#M_C4LF^/?VY5&USRO[_`(T%TXV5,/E3VX+?&N"XV[N//N=*A=4"K>WA
MRTX7HVN>=S\WP_*H<OCV7C4D2V'+CCRPM4?EN;V[_BO'\/SMVRXU/),.8OBF
M?%*PL;7O[O;4K=W=\W']/Q__V@`(`0$!!C\`M>->';5NGBTKYU5SF,&,EA<3
M;R*\`3(=&#XO1H<2O%4!YTQ(W7-5!$#54<<:Y>S\2,#F(VQDCI.>`4`G51I(
MJ"RVPKJH2"2[=J:EZ]0WUY=Y03ZE^2T#SMO((W9,90$HZ`RT3@HV+@[T35%,
MM$Z<5SE[D-[Z90$D2Y"2PVZVX+Y)X7&#!4(M&]'%4>^FBHJIT[QUR0H-9FS7
M?5TEO$BC!;R)B,VBSHTF&#S[3%O$$O(I@C3+P+J(HJ=M177TU[*G=41=.Z=]
M$7_MZ4C)!1$55551$1$]5[_@FO7MBP'+XY6DOW"<DM8G92!LF:U_CW#3=;K9
MG(5A%6'*&R@U60V$.&L?5O>CQFBFK2]:.$!DBEH0(0H0H9"BH)=R1!T^)/A)
M5U3MU/E5<"1:S8M=.EQ:J-)BPGK29%:1^)6LS)BC'BOV#S:,B;JBR*&JFJ(F
MO6/TGND]B/N6X@L\L8L9.,2!O^(<TQK(&*<8QVXU.3XYFCM<],JFI0'(C.(T
M^#9">U1+5*CE?B;^61[JLKXUOJR-<4=_:9GP=AUCD=',%'H5UB^,9%GD:?<0
MIK)(;)J3).M*A"BHJ:S?;]:1^0>`/<973K.KF<'^X'%W,+R@[>KW/2Z>GMFI
M%AC]W<,L."[]*U+5]V.GD9;,/C7>1"*^/S*"%O)&UW*)"@IN-"$=4T35>JV9
MSKR%]KR7(F]V(\9XM7'E?)67%YMC*46)U_DL$"4\0QD?E(Q%)]=@.*?;H,LX
M5_EL3,5PVPVRZ.R]TGN!QCB3++:N<`76ICO'U%C.:7="U,:=$V1ENMDB(NX4
MU3JI?]X?\N3E'`L=L35B/R'QGRWA')7'\Z>(2"2MAV[594`Q;2([)NA!GG&?
M)!U#=VZPW/JCR!2YOB>/9=6QWO$4B+#R2IBV\:++<91063$;D;"5-HZZI\2I
MKT9*ZC*#HI.KMT`45-Q?$)#KI^:=<,^Q2PA@N3<J<>7N8S\M>LPBU^(Y%N)S
M!L(<KRA(MI99M#@3E9-7@1HFVM457!'IM5W:J`JN]!0]=J:[T#X$+7UV]M?3
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MRE*9FW$8[KXT/KE;W`9&Q]U:XTPZ1.B5+3@*]>Y/.*-38_4+J8[&IV1S&Q?4
M?C1M"4=VU17FG^8O[H'WN2,TQS,6J/`)%\`V58QR([!&;9Y+25SV^!#K>/ZN
M7&K*>(*>"&:*Z`BZF_H2(S4U`/[Q2UW"WLW%M</^\^8AU)%5>^O7(7"7)=)#
MOL,Y&QJUQZSB36W'09?FQE&'9QE!Q@FK6LG>.3'-M1-LVM1)-53KB3B*\R9O
M,;?C3!,<P9_)DC.00NTQZ$W!8L!C>9UV&X_`C@AB>N\A^8NZ]9;G^42TK\7P
MG&[S+<AG&8,_25&.ULBVG/:DZR2$C$5=NB]RT3\>O;O_`#=K>5;U?('N)YVO
M,VBUSAHP7'F(4=C&M_:[708Y,B,+ZG"<7?9>-5!%>G-KH1.$I<5<SX@[Y\?Y
M+P:BS"*C0$B1G;.(TEC4OMNB+C<BKL@?8-24=IM*BHO]$Y':N5-<*[M@<:9E
MR(\8T>M)@*:)$:E/,D#BH*J@ZE\7X:HE>=/6-PDHLFB9%=8_$R*;?W$>C8AR
M8<:Y.J9&052-?:NMN/`GPHTA&2*B+TE;&>8?6R86*U%-H7G'WC:\2H3+`JJ-
M:("!XA<(E5-J:H6E']XIW;:RJ(+3MI"_4Q0I-%)(C!CS42DXYO*.:[GD5XOB
M7\UTXZ5B,D7_`-SME5IV6<M67/M\@3:4G662D`"D*D:CJJ=D45UZ(M434MJ*
M7S;13L)*2ZKHNJHGX(O]?660N-!?E<U\]W-1[>^&:B%M6R>S;DUQVF.WJVB$
ME>?IJA]Z4A#H#3H`9+V7JN]D/_YFYQ/XY3A^1Q7=VDCW#<%D]=R[>G?C9%F$
MIIZ61+;6F027[#>6KR.."2$)(FGN#]B'+`OXY=VB3KRIQ>P(7"J.2^,7!J\Q
MI(Y`+D7S6F*2&91;%TD#$5\/)N4D1$-#5%).P[-$0NP[.VFP51/V^OX]>U%5
M!9+2\O<C(0(X0>39QI9NK_F$1W8FK6B(J*FNBZ?"G7!W/O`G-?%N<\:8[P)Q
MK:7.#.<$1#Y`XUX]E8E5A!OJ6W*]LH6:NX?'<:6R-^*PYXP*2@;`,.LQ]SUD
MEUR+[^&;J3`YZY`Y6R!K)\OA2;D'6ZC(>/(K*1H&,8!E>/MBS#6"RA1R9.,1
MZ`J+G[E;',V:?D?B6XNT:-7D9IXF5,,OOON$*L*+5E+!2(NR]E5471$DU$,X
M0VM)SAR6WD(1U\#BSK5^'+AR'@`N_P!97.MDUK_AZ+ZHG2"G[J(GJJJFB)IJ
MJJJJNGY]%OT-"[*)JA"B)IVVK\.FJ_\`?TJMH.J?$&WTW+JB*J`J:BBJNOX)
MZ]<.^Q?A^HMLSY1]W&=0XV18GCMQ#H;A[@OCZ0UE')+3EE9.A!IHN2U\!*TY
MDLFXJ"X:%ZH*Y[[;$_EMYM@=1#QNK<X]NBYYX6FMX-9<>LPY>)V46BJ[%7I;
M$%FL\*0XY*KC:J*=R3KD[VNY+*$KOAC)#S?!XLM7&Y18!G,R4W;U34&8*/Q8
MF+9M'D-Z`'\-)@C\*;47K(J*P5ZNGP<GO8UC!\KK<F+("P,G'G#$/*\!1'1<
M;#4"T-/A[=08-<]]NIF7&;+(I_B:>M;H8`;DIW9![?%$)51L&4#<2.+N+776
MDR-O&L,J[6_N<CK[NSIZ6/%LZR*X2QX<NNDM*3C+M8[-WHZT0;5`E0E_!QBW
MDLNW4`'(D:^)H1?M8C#CS8Q[8Q)77G4:4C9<:)7'15&RU^+3!YJJDU:H;>VL
MGVA!!BP&(!QGWRU35-94A$$M4)"7LNO97IMG+@UL10%U^3:26($!IML"=<=6
M3+<9`-H.(I;B#Y575._6%T%;R)B=]PK[(>-,IR+CP"NJ\*C/>>K5Z#4W][C;
MLN7XKP\(AR?$#S"JV@MF0*J:%TKB&'A<1"(W!!^.OD^(U$T,A+>VB*FA;$'N
MOJG7%/NPXRRNGL++)$PKF?*<8H[J`]=0K;#+`<-RNGFP&9)-1V\[P]PQ$'Q5
M9!BZB>FHX]REPYGF/YGB>2UPV5?(J;-AR56$;(-RZVXK_.DZIL8$@U:?9=`-
MAAK\J(77M<X\JLTQNRSF%G_(F4S<8K[FNGVL''#PAV@:N9L2/8$<.')L[)MI
MA7=I.JI;!7:NGMBJL?R;#\[BL>WOCW"\HIX]K5W$B/*K,/B4F48UD%*$B5*8
ME1'HCS$J,^UJHH6Y%#5>L?YDXGB3I_M\Y(D65ABM;)=+[1D?&5I.23R-PK9O
M[Q6-DF`R'TFU#YZDC2Q]NU5=1<BQK$^0,1Y'XNYEP^=C5U"I+J*F0TWU\7^+
M%MJI9*VE'E&.3V?(C4AL7&WXJ$FH]^LUX>]UM59G[4N;[-@:SF*D@%.Q,K"G
M>^VXUR4VZT#@PI$NC>"+?U3B#(CJ@O-HZ@]JG-N-\KQ[.L0O(+$RHR/%+:#;
MTME%=%#"1'EP7Y#:*B:HH*J.)V141472QSWF?.*>!:#'),:X[K[&')SK-KU&
M"*+34=0+_P!0T$@MH/2Y#;<2.&IF6J"BM>Z7W2\E5U6O,F7\A<NQG,KR*HK<
M;XWXVF73\;#\1J)+ZPX;-+14U:BZH2FX\9%J2JB=>[KWE_K*EL*SC'&L<X`]
MN.,S+2(Q;L\=RGREY%G\*K?E#.VY;90W`%U`%"!T1+4M%4GY,AMD615'79BM
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MJ6Q#5'0!74%7D`E3XOBU[:Z:=3/MLN9D.5734=;O)+..+$N6D5D1"'7L--*%
M95&\2D38KHI=U[^C.$\R8/4\@8L%FQ>!17CLY8#EE`;-MB0\U$?BI(46GB16
MW")HT5=47IO'O^E_@=M^I8:D1HU)C%-4W$2*[_"1Y'J(H5Q'BJO\/<9H!+\/
M?TZ9QD(S+.-1J-O&VZS0_$E(,$:H:TW"-7$C)!`&]45#T3N7X]2?I?:GPM)>
M>38]+M<5BY)-,=$45^X7ZV<QDB;451!=W()+WT5=9V<\8\`<<8#E-I37&.6=
MIB=,5"LRBR",,.[KW8=7(B0"&PC`@$:M*8HGPJB]&M;[4>$G'9:-MN/W.&0[
MV<Z,,3;!M9>0C92R1E-$$=R(@]_33JNY6XT]OG&V`<@5I6)Q<CP^C*CD-N64
M%R'8.$Q6FQ7.N282D!$ZPJKKV5%7NSAG+_'N$\MTN-WT6_C8[D\>OOV*/((S
M+A0[`XQNJY"GNLO*J(:HIMNZ+J/;JAY-P7V[<6X7G6-.E(I<EQ+'F<<F0I#L
M%RO=D^"I^EA2GUBN*"$^VX7Q*NN[NLK%>0L2QK.<9G$IRZ'+:2OR"J>-$40<
M^BM6)3#;HBJZ$(H0JOPJ/4J9A_%U]Q6-@9NV-7Q%RGR?QM13GCU17I%'B>65
M=5YD!=!(&04$5=NGKT5^S[<\#RK)WH_TLW*N2V+#D_(Y[6KJH4NTSR??NNO?
MQ53?V)4_;WZPS'.1.#N.\JQGCJ,]#PC%9]&T&*8]%?)LW&(>,Q5CT7B(V15`
M..X+:HJCIJNM!DM=[8>'Z._QBR@7%':X[BL?'9L"RKI3<V+)1^B.M*4K$IH3
M!'D,-R=Q754ZR+`<]HH>38?EE>[6Y%13CDM1+:(ZX)G'>**ZU(C-F0(I*R8$
MI*J^OJY&@>T_@S8Z3CKK\_`ZBVG//.*GD-^?9L2Y[Y.Z:F1/*I*B:ZZ)HD;_
M`*4.(?MXS2G)3_9'_L223`1*1]@^J^R^12!%T\&W<F_YN_6B_FB_EW%4)/3\
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MF>('GG`15;30=>IG(;LYF7AR8K)S`+%&U^F?Q]:YZQ;<T,6SU?@;0)I05T7'
M-%3\L,9O*O((5ISAR!8SYUY`I"FXK1Y1E$F0[C6"2K@G0%;.#3@RWL9;=%D]
M1/OKU(M;ZW8JJ^(^U&\TAS?]1,E2%8A0(S`,/RI$F8\&T&FD(UW*@IV14S3#
MJ:KR9J5@<>J#(K&[ITJH,.ULV3E,4HMN&DM^V2"B2'=`%IIAP%71=R=9%C4=
MK*\@M<<Q]G($C8_CLFVDY-%>5]H1Q5J.(G9JT<5PG75!MA!$E0M-.H7(5R=S
M$J+"G6]A51TSHY-(B_2K..(50X(G'F18H*KR&J`T.I&8IMZP*.+F3MQN18,F
M906Y4*NTGUL6.+S^.%)84G9=Z#ABPC,9'A222-J9*BIUD%GC\3(*S]+Y'98I
M=0+^L"LL8EK5(V<D29/S--IL7OO--BKHH[E1$R:PO9ME,7$:MFXR"#C]4=Q+
MIXDM]`@):>/QQH+]HA(D9IQT'21=Q"B=UIK<H%C6.7%?%LDJ;AEEJRA#)C"Z
MW"L/I"=C19FWNXFXT$]13\-/]E"52T#4E055$+05[$B=R3OZ?BO5UC^"4]U8
M'?6E!4Y2UC$,;"^C87*LVTR635UP*)SI!5[)M;&U(U$UT3MU@5Y,Q61@7%G$
ME<\SQ;Q[8,"W?3;V9$;ANYCED1AZ2U`>B1C>")$,S>\CA/N[3VBF%0OT;9R>
M/>,*V'EL*]M?!%Q:^Y!GO'%";93&$*?9KAU.I_1Q`;5%FNB2Z"&].",_F8YD
M.98+Q_)S&VL*7'*Y;:XC9M(IVV\.L'JF(`.NM^;>`.JJ,QG50G5`5W+RUS/R
MJQ%H<PY0N7LPO:9N>%BQA.$XO7K'QW&WY+2$Q(L8-.T;LTVM6D?=5!)=$UY:
M9I<5R.OSGW89C+N+'++NM?;P[$N'WB9J:B<Q<:I%LI3&(LOC$A,"LDIDK^((
MMCY%PO@?CN!<'59%:81QU?7D3Z?_`.M\;U",OY);VCS@DZP=E55J1?A;(T>E
MHJ(B(I=<5QXO'E[QIQ3P+8VL^HH\MKXE;<9'F=.T[CN*RZR)#E2G/TS5UCC\
MU93A"<Y^0`Z)XR+K++&IXWR+,:[".-6+/B9]]B*U@\?,;$)3V1V]B\;OU-CE
M;$9&H4%EELG`:0A3;Y%<Z>DYW365;EN7VLO-<HEWAL?JF]R.Z-YZX?LZZ,Z]
M%J(<11:CPF`<+^`'Q"WN($Y-YKSG'WJ7->2LC>8JJ*4C0S,3X_J'7(E%!>`#
M=8:F6@1_J'P!!7XD3U3K#^'Z.JM8V)9G9*_R=G<48K#%+@U6H2)N.LR'B)Q+
M/*'0;9)!'3PB2KIVZY'YCJ>,+8+/B^C<XH]L''K,"-/E4U4WLA6/(PU[,HR<
ME33,G6%)PG%8;1?A)>IM9CN+%^M*C'K6XIJE^:5I<Y!EUC&<LI-MD`E_E#NY
M]TX;JQFW7Q:VB".+WTX-P:7Q-F#.!RWBY.Y0=RDX#%QF7)=4X$@UY'MDL'V:
M+'G+9Q'V8_\`&>>BL(/B1!;;Z960`!(5L/,+:[FD<1/B1HM$564+79KHNW37
M1=?]M?G_`+]C7Q;]_P"[_5MV^NG[NOX]-_GX7=-OGTVZ=]VG;;_O^+733IO3
M9IO+UU\.N\?EU^+=IZ?ANU_'3HM/%_@Z^/=Y_G3^]W?X&GII^WKF#Z3[]L_0
ME[]1^G/L'U7@\+WE^Z?>_P#,?8=-?JOI?\QX/+X^^WKCC_XWQ_H'%M/L6OV/
MQ_IR)I]F_P#5?3ZZ[=W\7UU[;>CTV:;&?^9MTT=T\N_XMF[\N_Y]NB_M:AOV
M^3=N\3>FG^#XM/FV?#NT_'I=WIYV_7UU_<V>+XO/_9_#9\W3NO\`9<^?79IL
M<T^GV]_)_P`S][77]G7;?Z#\^[7Y!_M=_P#?^W7H]?+ZIKM\NOJGIL_PM?73
M\>FM=FG;3Y_'\X:[-OQ?5>GS?N_\71^N[8O]WIMV^0]/#I_#TT_XOS[].;OI
GO_-M;?J-FFS1GT\??ZG7^YW_`!^OX=#\WRI\VN[T3YM>^[\_Z/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
